Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

SHP615

Phase 3 · small molecule · Nervous System Diseases

SHP615 for Nervous System Diseases is a Phase 3 program (small_molecule) at Takeda with 2 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 small molecule completed

Internal code SHP615-302

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
small_molecule
Indication
Nervous System Diseases
Status
completed
Trials
2

Clinical trials